Navigation Links
Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
Date:9/5/2007

Food and Drug Administration (FDA) and pixantrone has received fast track designation for this indication.

About RAPID (PIX203)

The RAPID trial is a first-line randomized phase II study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) with pixantrone to part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone and rituximab). The objective of the study is to demonstrate non-inferior complete response rates as the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. 280 patients are expected to be enrolled.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com. This press release includes forward-looking statements that involve a number of risks and
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Extended data analysis using DeCyder EDA
2. Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System
3. Techware to extend broadband wireless network to Butler
4. UW gets $5M to extend entrepreneurship
5. Creativity, innovation extend to municipalities
6. NimbleGen extends research market reach
7. TomoTherapy extends reach to Germany
8. Third Wave says patent extends IP reach
9. `Single-sales factor extends tax treatment to tech, service firms
10. Alumni Association extends database help to university
11. UW-Madison working to extend wireless access to entire campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Shimadzu Scientific Instruments ... multipurpose UV-visible spectrophotometer. Offering wavelength scanning from 190 ... ideal for applications in a variety of industries, ... The user-friendly UV-1280 enables intuitive operation, while the ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions ... a record-breaking year across the board for the company. ... Platform and our Smart Data solutions, our customers were able ... led to record growth for the company in 2014,” said ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... May 7 Dendreon Corporation (Nasdaq: DNDN ) today announced ... Bank of America and Merrill Lynch 2009 Health Care Conference, ... May 12, 2009, 9:20 a.m. ET, ... Tuesday, May 19, 2009, 4:35 p.m. ...
... Thursday, May 7, 2009 at 4:30 p.m. Eastern ... OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... results for the three months ended March 31, ... first quarter of 2009. , The following consolidated ...
... 6 Spectros Corporation (Portola Valley, CA) filed ... Scientific (NYSE: TMO ), alleging infringement ... 3300 product. Spectros invented and commercialized solid-state, broadband, ... and incorporated these into its flagship T-Stat product, ...
Cached Biology Technology:OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific 2
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Institute researcher Dr Matthew Call has been awarded ... Innovation (VESKI) Fellowship by the Victorian Government to ... and signalling. Dr Call,s research could signal ... treating immune diseases, using creative ,membrane mimic, technology ...
... born to mothers who are fed a diet supplemented with ... scientists at the Jean Mayer USDA Human Nutrition Research Center ... research in humans and mice suggests that B vitamins, particularly ... Using a mouse model of naturally occurring colorectal cancer, the ...
... Ariz. June 9, 2011 TGen Drug Development ... the rapid development of anti-cancer drugs and deliver them ... "The highest quality medical imaging provided by Imaging ... Dr. Stephen Gately, President of TD2, which assists drug ...
Cached Biology News:Structural biologist wins $150K for 'membrane mimic' technology 2B vitamins in mother's diet reduce colorectal cancer risk in offspring 2TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services 2
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
Automated Cell Culture Flask...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: